GSH-Responsive GalNAc-Conjugated Glycopolymer for Targeted Survivin siRNA Delivery in Hepatocellular Carcinoma Therapy.
Sign Up to like & getrecommendations! Published in 2025 at "ACS macro letters"
DOI: 10.1021/acsmacrolett.5c00121
Abstract: Gene interference therapy has made significant progress in the treatment of various diseases by targeting specific pathogenic genes and down-regulating the production of harmful proteins. This approach enables the precise modulation of gene expression, offering… read more here.
Keywords: galnac conjugated; therapy; liver cancer; conjugated glycopolymer ... See more keywords
Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates
Sign Up to like & getrecommendations! Published in 2024 at "Nucleic Acids Research"
DOI: 10.1093/nar/gkae350
Abstract: Abstract Oral delivery is the most widely used and convenient route of administration of medicine. However, oral administration of hydrophilic macromolecules is commonly limited by low intestinal permeability and pre-systemic degradation in the gastrointestinal (GI)… read more here.
Keywords: galnac conjugated; delivery; oral delivery; rodents non ... See more keywords
The Nonclinical Safety Profile of GalNAc-conjugated RNAi Therapeutics in Subacute Studies
Sign Up to like & getrecommendations! Published in 2018 at "Toxicologic Pathology"
DOI: 10.1177/0192623318792537
Abstract: Short interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) are the most clinically advanced oligonucleotide-based platforms. A number of N-acetylgalactosamine (GalNAc)-conjugated siRNAs (GalNAc-siRNAs), also referred to as RNA interference (RNAi) therapeutics, are currently in various stages… read more here.
Keywords: rnai therapeutics; galnac conjugated; safety; galnac sirnas ... See more keywords